Châtenay-Malabry, France

Serguei Nabirochkin

This inventor holds 52 USPTO granted patents and 16 published patent applications, plus 18 CIPO patents and 33 EPO patents, primarily in Neurological Disorders (CPC class A61K). Top assignee: Pharnext. Active years: 2013-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Serguei Nabirochkin. Retrieved from https://idiyas.com/inventor/serguei-nabirochkin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 52 

% Patents Active = 51.9

 

 

Average Co-Inventor Count = 3.9

ph-index = 9

Forward Citations = 208(Granted Patents)

Forward Citations (Not Self Cited) = 25(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Catenay Malabry, FR (2020)
  • Chateney-Malabry, FR (2020)
  • Chatenay Malabry, FR (2013 - 2023)

Company Filing History:


Years Active: 2013-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
CMT Disease
Alzheimer's Disease
Neurological Disorders
Diabetes Management
Angiogenesis Modulation
Nootropic Compositions
Biomarker Detection
Parkinson's Disease
Amyotrophic Lateral Sclerosis
Stable Oral Solutions
Synapse Function
Therapeutic Approaches
52 patents (USPTO):Explore Patents

Title: Serguei Nabirochkin: Innovator in Charcot-Marie-Tooth Disease Research

Introduction

Serguei Nabirochkin, located in Chatenay Malabry, France, is a prominent inventor with an impressive portfolio of 52 patents. His work primarily focuses on innovations in medical treatments, particularly in addressing Charcot-Marie-Tooth Disease (CMT), a group of inherited disorders that affect the peripheral nerves.

Latest Patents

Among his latest innovations are two significant patents that aim to improve the lives of those afflicted by CMT. The first patent outlines methods for treating, preventing, or delaying the onset of Charcot-Marie-Tooth Disease type 1A (CMT1A). This method involves administering a combination of baclofen, sorbitol, and naltrexone, or a pharmaceutically acceptable salt thereof, to subjects in need. The second patent relates to compositions and methods for treating CMT and related disorders, showcasing his dedication to advancing medical science in this field.

Career Highlights

Serguei Nabirochkin has established a noteworthy career at Pharnext, where he has played a pivotal role in developing therapies for neurological conditions. His extensive work has not only contributed to the scientific community but also has the potential to benefit countless individuals suffering from CMT.

Collaborations

Throughout his career, Nabirochkin has collaborated with accomplished colleagues, including Daniel Cohen and Ilya Chumakov. This collaborative spirit fosters an environment of innovation and enhances the likelihood of successful breakthroughs in treatment methodologies.

Conclusion

Serguei Nabirochkin's significant contributions to the field of medicine highlight the vital role inventors play in advancing healthcare. Through his innovative patents, he continues to lead the way in finding solutions for Charcot-Marie-Tooth Disease, exemplifying the impact of dedication and creativity in the scientific community.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…